Literature DB >> 11096718

Restless Legs Syndrome.

.   

Abstract

With suitable pharmacotherapy, patients with any degree of restless legs syndrome (RLS) should be able to obtain substantial relief of symptoms. The best therapeutic success is attained when the physician tailors therapy to the patient's specific symptoms and can flexibly try a variety of agents, if needed. Therapy should be reserved for those in whom RLS cannot be managed with just sleep hygiene and related practices. It should not be withheld, however, if a patient reasonably believes that his or her quality of life is being impaired by RLS. The optimal initial approach to RLS in the general patient is usually the use of a dopaminergic agent: low-dose levodopa in milder cases, a dopamine agonist in more severe ones. Patients whose problems are primarily sleep related can initially be treated with a benzodiazepine. Patients who have symptoms primarily while awake can initially be treated with a dopaminergic agent or an opioid. Patients whose RLS discomfort is truly painful can initially be treated with gabapentin. Combination therapy with two or three agents from different classes can be useful as well. Determination of iron status is the most important initial laboratory evaluation in patients with RLS. Iron supplementation should be used as indicated. In the future, delivery modes other than oral administration of medications may be of significant benefit, especially in more severe cases.

Entities:  

Year:  1999        PMID: 11096718     DOI: 10.1007/s11940-999-0021-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  48 in total

1.  Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

Authors:  N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

2.  Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Authors:  J Staedt; F Wassmuth; U Ziemann; G Hajak; E Rüther; G Stoppe
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.

Authors:  C Brodeur; J Montplaisir; R Godbout; R Marinier
Journal:  Neurology       Date:  1988-12       Impact factor: 9.910

4.  Effect of pramipexole in treatment of resistant restless legs syndrome.

Authors:  S C Lin; J Kaplan; C D Burger; P A Fredrickson
Journal:  Mayo Clin Proc       Date:  1998-06       Impact factor: 7.616

Review 5.  An overview of levodopa in the management of restless legs syndrome in a dialysis population: pharmacokinetics, clinical trials, and complications of therapy.

Authors:  L Janzen; J A Rich; L M Vercaigne
Journal:  Ann Pharmacother       Date:  1999-01       Impact factor: 3.154

6.  Treatment of the restless legs syndrome with carbamazepine: a double blind study.

Authors:  W Telstad; O Sørensen; S Larsen; P E Lillevold; P Stensrud; R Nyberg-Hansen
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-11

7.  Comparison of cognitive-behavioral therapy and clonazepam for treating periodic limb movement disorder.

Authors:  J D Edinger; A I Fins; R J Sullivan; G R Marsh; D S Dailey; M Young
Journal:  Sleep       Date:  1996-06       Impact factor: 5.849

8.  L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.

Authors:  C Trenkwalder; K Stiasny; T Pollmächer; T Wetter; J Schwarz; R Kohnen; J Kazenwadel; H P Krüger; S Ramm; M Künzel
Journal:  Sleep       Date:  1995-10       Impact factor: 5.849

9.  Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up.

Authors:  C von Scheele; V Kempi
Journal:  Arch Neurol       Date:  1990-11

10.  Myoclonus with burning sensation in legs that remits with sympathetic blockade.

Authors:  T Uchihara; T Ichikawa; T Furukawa; H Tsukagoshi
Journal:  J Neurol Sci       Date:  1990-12       Impact factor: 3.181

View more
  3 in total

1.  Sleep fragmentation and motor restlessness in a Drosophila model of Restless Legs Syndrome.

Authors:  Amanda Freeman; Elaine Pranski; R Daniel Miller; Sara Radmard; Doug Bernhard; H A Jinnah; Ranjita Betarbet; David B Rye; Subhabrata Sanyal
Journal:  Curr Biol       Date:  2012-05-31       Impact factor: 10.834

Review 2.  Restless legs syndrome in the older adult: diagnosis and management.

Authors:  Shawn A Milligan; Andrew L Chesson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Fibromyalgia: progress in diagnosis and treatment.

Authors:  Dina Dadabhoy; Daniel J Clauw
Journal:  Curr Pain Headache Rep       Date:  2005-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.